Loading
A phase 2 trial of Axitinib, Lenvatinib and Pembrolizumab in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer is a phase 2 interventional study registered as NCT06962787 by Sichuan Baili Pharmaceutical Co., Ltd., with 260 participants planned, started 2025-07-28 and due to reach its primary completion in 2027-05. Interventions recorded: BL-B01D1, Axitinib, Lenvatinib and Pembrolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SystImmune / Sichuan Biokin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Lenvatinib, Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/